Andrew Nichols - Catabasis Pharmaceuticals Sr. VP of Research
SVP
Dr. Andrew Nichols, Ph.D., serves as Chief Scientific Officer of the Company. Previously, he served as our Senior Vice President, Research and Development from February 2014 to October 2016. From October, 2013 to February, 2014, Dr. Nichols was Associate Vice President, Cardiometabolic Diseases at Merck Research Labs, a pharmaceutical research company, leading drug discovery and early clinical development programs since 2016.
| Age | 56 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 617 349 1971 |
| Web | http://www.catabasis.com |
Catabasis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (20.32) % which means that it has lost $20.32 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (210.26) %, meaning that it created substantial loss on money invested by shareholders. Catabasis Pharmaceuticals' management efficiency ratios could be used to measure how well Catabasis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 713 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Catabasis Pharmaceuticals has a current ratio of 34.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Catabasis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Catabasis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Catabasis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Catabasis to invest in growth at high rates of return. When we think about Catabasis Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company was incorporated in 2008 and is based in Boston, Massachusetts. Catabasis Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. Catabasis Pharmaceuticals (CATB) is traded on NASDAQ Exchange in USA and employs 20 people. Management Performance
| Return On Equity | -210.26 | |||
| Return On Asset | -20.32 |
Catabasis Pharmaceuticals Leadership Team
Elected by the shareholders, the Catabasis Pharmaceuticals' board of directors comprises two types of representatives: Catabasis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catabasis. The board's role is to monitor Catabasis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Catabasis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catabasis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jean George, Director | ||
| Angelika Fretzen, Senior Vice President - Product Development | ||
| Gregg Lapointe, Director | ||
| Rick Modi, Chief Business Officer | ||
| Joanne Donovan, Chief Medical Officer | ||
| Deirdre Cunnane, Senior Vice President General Counsel | ||
| Michael Jirousek, Co-Founder and Member of Scientific Advisory Board | ||
| Michael Kishbauch, Director | ||
| Edward Hibben, Chief Business Officer | ||
| Joanne Beck, Director | ||
| Ian Sanderson, CFO, Treasurer | ||
| Burt Adelman, Director | ||
| Deirdre JD, Sr. VP and General Counsel | ||
| Kenneth Bate, Director | ||
| Hugh Cole, Director | ||
| Jill Milne, Co-Founder, CEO and President and Director | ||
| Andrea Matthews, IR Contact Officer | ||
| Nicholas Galakatos, Director | ||
| Ron Laufer, Director | ||
| Michael Ross, Chairman of the Board | ||
| Andrew Nichols, Sr. VP of Research | ||
| Ted Hibben, Sr. VP of Corporate Devel. |
Catabasis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catabasis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -210.26 | |||
| Return On Asset | -20.32 | |||
| Current Valuation | 58.17 M | |||
| Shares Outstanding | 76.95 M | |||
| Shares Owned By Insiders | 0.03 % | |||
| Shares Owned By Institutions | 54.77 % | |||
| Number Of Shares Shorted | 96.27 K | |||
| Price To Earning | (1.24) X | |||
| Price To Book | 0.98 X | |||
| Price To Sales | 258.49 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Catabasis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Catabasis Pharmaceuticals' short interest history, or implied volatility extrapolated from Catabasis Pharmaceuticals options trading.
Pair Trading with Catabasis Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catabasis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catabasis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Intel could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Intel when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Intel - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Intel to buy it.
The correlation of Intel is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Intel moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Intel moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Intel can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Catabasis Stock
If you are still planning to invest in Catabasis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catabasis Pharmaceuticals' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |